Tejara Capital Ltd Decreases Stock Holdings in Schrödinger, Inc. (NASDAQ:SDGR)

Tejara Capital Ltd trimmed its position in shares of Schrödinger, Inc. (NASDAQ:SDGR) by 21.6% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 80,907 shares of the company’s stock after selling 22,328 shares during the period. Schrödinger accounts for about 1.0% of Tejara Capital Ltd’s investment portfolio, making the stock its 27th biggest holding. Tejara Capital Ltd’s holdings in Schrödinger were worth $1,561,000 as of its most recent filing with the SEC.

Other hedge funds have also modified their holdings of the company. Avanza Fonder AB purchased a new stake in shares of Schrödinger during the fourth quarter valued at about $577,000. Barclays PLC raised its position in shares of Schrödinger by 421.6% in the 3rd quarter. Barclays PLC now owns 107,554 shares of the company’s stock valued at $1,995,000 after purchasing an additional 86,933 shares during the last quarter. State Street Corp raised its position in shares of Schrödinger by 1.8% in the 3rd quarter. State Street Corp now owns 2,155,620 shares of the company’s stock valued at $39,987,000 after purchasing an additional 38,972 shares during the last quarter. Quest Partners LLC raised its position in shares of Schrödinger by 861.0% in the 3rd quarter. Quest Partners LLC now owns 43,773 shares of the company’s stock valued at $812,000 after purchasing an additional 39,218 shares during the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. raised its position in shares of Schrödinger by 60.2% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,510,518 shares of the company’s stock valued at $67,718,000 after purchasing an additional 1,319,464 shares during the last quarter. 79.05% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on SDGR. Piper Sandler decreased their price objective on shares of Schrödinger from $50.00 to $45.00 and set an “overweight” rating for the company in a research report on Thursday, February 27th. KeyCorp increased their price objective on shares of Schrödinger from $25.00 to $27.00 and gave the company an “overweight” rating in a research report on Friday, January 24th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Schrödinger has a consensus rating of “Buy” and a consensus price target of $32.29.

Insiders Place Their Bets

In other news, CFO Geoffrey Craig Porges sold 5,491 shares of the firm’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $21.76, for a total transaction of $119,484.16. Following the sale, the chief financial officer now owns 27,544 shares of the company’s stock, valued at $599,357.44. This trade represents a 16.62 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 8.60% of the stock is currently owned by insiders.

Schrödinger Trading Up 3.6 %

SDGR opened at $23.73 on Tuesday. Schrödinger, Inc. has a 12-month low of $16.67 and a 12-month high of $29.15. The firm has a market capitalization of $1.73 billion, a PE ratio of -10.14 and a beta of 1.62. The firm has a 50 day moving average of $22.75 and a two-hundred day moving average of $20.72.

Schrödinger (NASDAQ:SDGR) last posted its quarterly earnings results on Wednesday, February 26th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.20). Schrödinger had a negative return on equity of 35.77% and a negative net margin of 91.84%. The business had revenue of $88.32 million for the quarter, compared to analysts’ expectations of $83.20 million. As a group, analysts predict that Schrödinger, Inc. will post -2.37 EPS for the current fiscal year.

Schrödinger Company Profile

Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.